PMID: 7654486Jun 1, 1995

A double-blind, placebo controlled study of the effect of the specific histamine H1-receptor antagonist, terfenadine, in chronic severe asthma

British Journal of Clinical Pharmacology
R Wood-BakerS T Holgate


1. The characteristic changes seen in asthma are widely regarded as being caused by local mediator release in the airways, with histamine the first putative mediator in asthma to be identified. 2. We performed a double-blind, randomised, placebo-controlled crossover trial of the effect of 4 weeks treatment with terfenadine 120 mg twice daily in chronic severe asthma. 3. Forty-two subjects (20 male and 22 female) completed the 10 week study. 4. Terfenadine had no significant treatment effect on the primary efficacy variables measured. Mean (95% CI) measurements for terfenadine vs placebo treatment periods were 1.5 vs 1.5 (-0.3, 0.3) l for FEV1, 259 vs 260 (-42, 40) l min-1 for morning PEF and 0.8 vs 0.8 (-0.3, 0.3) for global symptom scores. 5. Bronchodilator use and sleep disturbance, the secondary efficacy variables studied, showed an improvement during terfenadine treatment but this only reached statistical significance for the number of times subjects awoke from sleep (P = 0.04). 6. There was a similar frequency of minor adverse effects reported during placebo (13.6%) and terfenadine (16.7%) treatments. 7. Addition of the potent and specific histamine H1-receptor antagonist terfenadine to maintenance asthma treatment had no ...Continue Reading


Oct 8, 2003·The Journal of Allergy and Clinical Immunology·Gianni MaroneMassimo Triggiani
Oct 8, 2003·The Journal of Allergy and Clinical Immunology·Harold S Nelson
Feb 1, 1997·The Journal of Allergy and Clinical Immunology·J Corren
May 17, 2000·Current Opinion in Pulmonary Medicine·J Corren
Jan 1, 1997·Allergy·A Malick, J A Grant
May 16, 2006·Treatments in Respiratory Medicine·Andrew M Wilson
Aug 12, 1999·Clinical and Experimental Allergy : Journal of the British Society for Allergy and Clinical Immunology·F E Simons
Jul 5, 2005·Expert Opinion on Investigational Drugs·D A HandleyA J Higgins


Aug 1, 1990·British Journal of Clinical Pharmacology·P RaffertyS T Holgate
Sep 1, 1990·Clinical and Experimental Allergy : Journal of the British Society for Allergy and Clinical Immunology·J H DijkmanE H Van Ganse
Aug 1, 1990·The American Review of Respiratory Disease·R DjukanovićS T Holgate
Mar 11, 1989·Lancet·W R RocheS T Holgate
Nov 1, 1989·The Journal of Allergy and Clinical Immunology·W W Busse, C A Swenson
Feb 1, 1987·The Journal of Allergy and Clinical Immunology·K R Patel
Feb 1, 1985·The Journal of Allergy and Clinical Immunology·M J Cushley, S T Holgate
Dec 1, 1987·British Journal of Clinical Pharmacology·A TaytardP J Lewis
Apr 1, 1985·Agents and Actions·J G de MonchyK de Vries
Jul 1, 1984·The Journal of Allergy and Clinical Immunology·S R DurhamA B Kay
Mar 24, 1993·JAMA : the Journal of the American Medical Association·R L WoosleyR A Gillis
Nov 1, 1946·The Journal of Clinical Investigation·J J Curry
Dec 31, 1910·The Journal of Physiology·H H Dale, P P Laidlaw

Related Concepts

Histamine Measurement
Sleep, Slow-Wave
Peak Expiratory Flow Rate Measurement
Antagonist Muscle Action
Cross-Over Studies
Adverse Effects
Bronchodilator Agents

Related Feeds


This feed focuses in Asthma in which your airways narrow and swell. This can make breathing difficult and trigger coughing, wheezing and shortness of breath.

Allergy and Asthma

Allergy and asthma are inflammatory disorders that are triggered by the activation of an allergen-specific regulatory t cell. These t cells become activated when allergens are recognized by allergen-presenting cells. Here is the latest research on allergy and asthma.

Absence Epilepsy

Absence epilepsy is a common seizure disorder in children which can produce chronic psychosocial sequelae. Discover the latest research on absence epilepsies here.

© 2020 Meta ULC. All rights reserved